Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
07 mars 2023 08h00 HE
|
Ocugen
MALVERN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
06 mars 2023 07h02 HE
|
Ocugen
MALVERN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
28 févr. 2023 07h00 HE
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Completed retinitis pigmentosa patient enrollment in OCU400 Phase 1/2 clinical trial Continued progress for programs targeting eye diseases with the...
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
27 févr. 2023 17h57 HE
|
Ocugen
MALVERN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
17 févr. 2023 08h00 HE
|
Ocugen
MALVERN, Pa., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
15 févr. 2023 16h30 HE
|
Ocugen
MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Appoints Quan A. Vu as Chief Business Officer
01 févr. 2023 08h00 HE
|
Ocugen
MALVERN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
31 janv. 2023 08h00 HE
|
Ocugen
MALVERN, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
09 janv. 2023 06h00 HE
|
Ocugen
Study met both co-primary endpoints with robust immune responses COVAXIN™ was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the...
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
16 déc. 2022 06h30 HE
|
Ocugen
MALVERN, Pa., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...